Fengjuan Fan

Union Hospital
Wuhan, 430022, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

U-shaped Association of Third-trimester Serum Uric Acid with Postpartum Hemorrhage: Statistical Mediation Effects of Hemoglobin, Fibrinogen, and D-dimer-A Multicenter Cohort Study.

U-shaped Association of Third-trimester Serum Uric Acid with Postpartum Hemorrhage: Statistical Mediation Effects of Hemoglobin, Fibrinogen, and D-dimer-A Multicenter Cohort Study.

Journal: Thrombosis and haemostasis

Published: January 28, 2026

Methionine Dependency and Restriction in Cancer: Exploring the Pathogenic Function and Therapeutic Potential.

Methionine Dependency and Restriction in Cancer: Exploring the Pathogenic Function and Therapeutic Potential.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: March 24, 2025

Therapeutic Target Discovery for Multiple Myeloma: Identifying Druggable Genes via Mendelian Randomization.

Therapeutic Target Discovery for Multiple Myeloma: Identifying Druggable Genes via Mendelian Randomization.

Journal: Biomedicines

Published: February 19, 2025

COMMD3 Regulates Copper Metabolism via the ATOX1-ATP7A-LOX Axis to Promote Multiple Myeloma Progression.

COMMD3 Regulates Copper Metabolism via the ATOX1-ATP7A-LOX Axis to Promote Multiple Myeloma Progression.

Journal: Biomedicines

Published: December 27, 2024

Risk of cardiovascular disease among cancer survivors: systematic review and meta-analysis.

Risk of cardiovascular disease among cancer survivors: systematic review and meta-analysis.

Journal: EClinicalMedicine

Published: December 22, 2024

LDHAL6B is a novel prognostic marker and promotes disease progression in multiple myeloma.

LDHAL6B is a novel prognostic marker and promotes disease progression in multiple myeloma.

Journal: Haematologica

Published: October 24, 2024

Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity.

Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity.

Journal: Blood cancer journal

Published: April 13, 2024

Correction: Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.

Correction: Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.

Journal: Breast cancer research : BCR

Published: April 02, 2024

Class II ferroptosis inducers are a novel therapeutic approach for t(4;14)-positive multiple myeloma.

Class II ferroptosis inducers are a novel therapeutic approach for t(4;14)-positive multiple myeloma.

Journal: Blood advances

Published: December 13, 2023

Advances in nano-immunotherapy for hematological malignancies.

Advances in nano-immunotherapy for hematological malignancies.

Journal: Experimental hematology & oncology

Published: November 25, 2023

Platelet RNA sequencing reveals profile of caffeic acid affecting hemostasis in mice.

Platelet RNA sequencing reveals profile of caffeic acid affecting hemostasis in mice.

Journal: Research and practice in thrombosis and haemostasis

Published: April 18, 2023

ACSL4: a double-edged sword target in multiple myeloma, promotes cell proliferation and sensitizes cell to ferroptosis.

ACSL4: a double-edged sword target in multiple myeloma, promotes cell proliferation and sensitizes cell to ferroptosis.

Journal: Carcinogenesis

Published: February 02, 2023

Showing 1-12 of 44

Last Updated: 09/26/2026